Form 4: BioCryst Pharmaceuticals CEO Jon P. Stonehouse Reports Transactions in Company Stock

Jon P. Stonehouse, President and CEO of BioCryst Pharmaceuticals, reports acquisition and disposal of company stock and derivative securities.

Summary

• On December 19, 2024, Jon P. Stonehouse, the President and CEO of BioCryst Pharmaceuticals, acquired 362,100 shares of common stock as an annual award of Restricted Stock Units.
• These Restricted Stock Units will vest 25% on each of the first, second, third, and fourth anniversaries of the grant date.
• On the same day, 14,010 shares were disposed of to cover tax withholding obligations related to the vesting of previously granted Restricted Stock Units at a price of $7.39 per share.
• On December 20, 2024, Stonehouse gifted 10,000 shares each to the Samuel Stonehouse Irrevocable Trust and the Caroline Stonehouse Irrevocable Trust.
• Also on December 19, 2024, Stonehouse acquired 750,250 employee stock options with an exercise price of $7.39, which become exercisable at a rate of 25% on each of the first, second, third and fourth anniversaries of the grant date, expiring on December 19, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing primarily reflects routine compensation-related transactions. The stock and option grants are a positive sign, but the tax-related disposal is a minor negative.

Positives

• The grant of 362,100 Restricted Stock Units to the CEO could be seen as an incentive to drive company performance.
• The grant of 750,250 employee stock options to the CEO could be seen as an incentive to drive company performance.

Negatives

• The disposal of 14,010 shares to cover tax obligations, while routine, slightly reduces the CEO's direct holdings.

Risks

• The vesting schedule of the Restricted Stock Units and stock options means the CEO's incentives are tied to long-term performance, but short-term fluctuations in stock price could impact the perceived value of these awards.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Investors often monitor these filings to gauge management's sentiment and confidence in the company's prospects.

Comparison to Industry Standards

• Stock option grants and restricted stock units are common forms of executive compensation in the pharmaceutical industry.
• Companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals also utilize these instruments to align executive incentives with shareholder value.
• The vesting schedules and exercise prices are generally in line with industry norms for companies of similar size and stage of development.

Related Party Transactions

• The gifts of shares to the Samuel Stonehouse Irrevocable Trust and the Caroline Stonehouse Irrevocable Trust are related-party transactions.

Stakeholder Impact

• The stock and option grants align the CEO's interests with those of shareholders.
• The vesting schedules encourage long-term value creation.

Key Dates